Sun Pharmaceutical
Industries Limited

Sun Pharmaceutical Industries was established in 1983 with five psychiatry products and a two-person marketing team, and set up its first tablet and capsule manufacturing facility at Vapi in Gujarat. Cardiology products followed in 1988 with the launch of Monotrate and Angize.

The company established its first research centre in 1991 — unusually early for an Indian company of that size — and listed on the Indian stock exchanges in 1994 in an offering oversubscribed 55 times. The founding family has retained majority ownership since.

Through the second half of the 1990s the company integrated backwards into active pharmaceutical ingredients and widened its dosage-form capability. It commissioned an API plant at Panoli in 1995, acquired a bulk-drug facility at Ahmednagar from Knoll Pharmaceuticals in 1996 and extended its sales network to 24 countries in the same year.

Acquisitions and new plants followed in sequence: equity stakes in Tamil Nadu Dadha Pharmaceuticals and MJ Pharma and a Mumbai research facility in 1997; Milmet Labs and a 7-ADCA site in 1999; Pradeep Drug Company in 2000; formulation units at Silvassa (1998), Dadra (2001) and Jammu (2004); a joint-venture unit in Dhaka in 2004; the Bryan, Ohio manufacturing buyout and ICN’s Hungarian business in 2005; Chattem Chemicals in 2008.

In 2007 the company demerged its innovative research arm as Sun Pharma Advanced Research Company Limited (SPARC), a separately listed entity working on new chemical entities and drug-delivery technologies. Dilip Shanghvi chairs SPARC.

Sun Pharma entered the United States in 1997 with the acquisition of Caraco Pharmaceutical Laboratories of Detroit, and expanded decisively there in 2010 by acquiring a controlling stake in Taro Pharmaceutical Industries of Israel. The 2015 Ranbaxy merger added a further international footprint, and the company entered Japan through fourteen prescription brands acquired from Novartis in 2016 and Pola Pharma in 2019. It entered the Greater China market in 2019.

Approximately two-thirds of the company’s revenue is now earned outside India, with the United States and India together accounting for the majority of turnover.

Source: Sun Pharmaceutical Industries, Q4 & FY2026 results, May 2026; company corporate profile.

Sun Pharma invests six to eight per cent of global revenue in research and development each year. In the financial year ended March 2026 that investment was ₹3,554 crore, equal to 6.1 per cent of sales. More than 2,900 scientists and technical staff work in formulation development and chemistry.

The company’s technical capability is concentrated in complex and differentiated dosage forms rather than in commodity tablets: liposomal drugs, inhalers, lyophilised injections, nasal sprays and controlled-release formulations. As at the close of the 2026 financial year it held 552 approved abbreviated new drug applications and 57 approved new drug applications in the United States, and had five novel entities in clinical development.

Long-horizon discovery work sits in the separately listed Sun Pharma Advanced Research Company, allowing the commercial business to be measured on commercial outcomes while new-molecule research is funded and judged on its own terms.

The company operates 41 manufacturing facilities across India, the United States, Asia, Africa, Australia and Europe, supplying more than a hundred countries and the therapeutic areas of neuro-psychiatry, cardiology, gastroenterology, anti-infectives, diabetology, oncology, ophthalmology, dermatology, urology, nephrology and respiratory medicine.

Regulatory oversight of a manufacturing network of this size is continuous. Sun Pharma’s facility at Halol in Gujarat received a warning letter from the United States Food and Drug Administration following a 2022 inspection and was placed under an import alert in December 2022, with certain products excluded on drug-shortage grounds. Following a further inspection in June 2025 the site remained classified Official Action Indicated, as the company disclosed in September 2025. An earlier import alert on the Mohali facility, inherited through the Ranbaxy merger, was lifted in March 2017.

Sources: US FDA warning letters and import alert notices; Sun Pharma stock-exchange intimations, December 2022 and September 2025.

Dilip Shanghvi is Founder and Executive Chairman. Kirti Ganorkar, who joined the company in the mid-1990s and led its India business from 2019, was appointed Managing Director with effect from 1 September 2025. Aalok Shanghvi and Vidhi Shanghvi serve as executive directors, and Kalyanasundaram Subramanian is an executive director. The board also includes a lead independent director and a group of independent directors drawn from industry, medicine, finance and market research.

The company is listed on the BSE and the National Stock Exchange of India and is a constituent of both the SENSEX and the NIFTY 50.